Schizophrenia.com
Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study
News
everhopeful
June 15, 2021, 4:21pm
1
5 Likes
RottenApple
June 15, 2021, 4:47pm
2
Sounds promising!
1 Like
Related topics
Topic
Replies
Views
Activity
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
News
4
423
December 13, 2018
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia
News
4
443
April 16, 2020
Trial for sep 363856
Medications
1
321
July 31, 2022
Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint
News
2
456
December 13, 2018
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
News
9
1198
November 23, 2016